Posted on

How Gilead Profited by Slow-Walking a Promising H.I.V. Therapy

In 2004, Gilead Sciences decided to stop pursuing a new H.I.V. drug. The public explanation was that it wasn’t sufficiently different from an existing treatment to warrant further development.In private, […]




Posted on

Gilead Wins Key Patent Rights Suit Over PrEP Drugs for Preventing HIV

A federal jury in Delaware on Tuesday found that the federal government did not have an ownership claim to lucrative drugs to prevent H.I.V. that are sold by the pharmaceutical […]